NCI Panel Exploring Integrated Cancer Clinical Trials System
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency expert group will focus on four immediate impediments to an integrated system: coordination, prioritization, timeliness and regulation. The panel also plans to develop a blueprint for a clinical trial system for the future.
You may also be interested in...
National Cancer Institute Is Model For Central Institutional Review Board – Draft Guidance
FDA's draft guidance on centralized IRB review suggests creating regional or nonregional cooperatives as an alternate model. The document also makes recommendations for centralized IRB written procedures.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.